Skip to main content
Donate

Spoken Language Comprehension in Children and Adults with Angelman Syndrome

This FAST-funded study aimed to evaluate a highly sensitive and objective method to measure receptive language in individuals living with Angelman syndrome, a vital need for clinical trials. When individuals have limited expressive verbal language due to a combination of challenges (gross motor, fine motor, dyspraxia, etc.), their standardized scores on receptive language tests are negatively impacted. This study evaluated a way to try and circumvent that to better assess receptive language without needing expressive language or advanced motor skills. The conclusion was that eye tracking during listening demonstrated increased receptive language skills through an increased probability of looks to the target images after they were named in a spoken sentence. However, processing speeds (gaze reaction time) were significantly slower in AS than in a typically developing group. Overall, this method of eye-gaze testing may offer an informative and complementary approach to evaluating receptive language skills in AS, especially in participants who are unable to complete traditional standardized assessments of receptive language. In addition, individuals with AS may have less efficient speech processing and/or specific visual attention disengagement difficulties, which are likely separate from nonverbal cognitive function.

Click here to learn more about this research study.

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.